Darmstadt, Germany (ots/PRNewswire) - - Data suggests Mavenclad may significantly increase proportion of patients exhibiting no evidence of disease activity versus placebo - Analysis of 10,000 patient years of safety data provides further characterization of safety profile - Further data suggests the relative ...
Haifa, Israel (ots/PRNewswire) - INSIGHTEC (http://www.insightec.com), the world leader of MR-guided Focused Ultrasound announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate a pivotal study of the Exablate Neuro for treating dyskinesia symptoms or motor ...
Darmstadt, Germany (ots/PRNewswire) - - Multiple sclerosis diagnosis has a profound impact on life choices including education, career, family planning and relationships - Almost 90% of women say multiple sclerosis played a role in their separation or divorce following diagnosis - Policy interventions could help address significant gender-specific challenges Merck, a ...
Zurich (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, today announced that Prof. Florence Wong, University of Toronto, presented the findings of the MOSAIC study data at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting (The ...
Hong Kong (ots/PRNewswire) - - Program to include late-breaking presentation of REDUCE clinical trial - Data on more than 5,000 patients to be presented OrbusNeich, a global company specialising in the provision of life-changing vascular solutions, has today announced a schedule of events at the 29th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation, ...
Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (NASDAQ: ARAY) announced today that the Court of Appeal of Nantes has rejected the appeal filed by Varian Medical Systems opposing the purchase of the Accuray TomoTherapy® System by University Hospital of Tours (CHU). This most recent legal ruling marks ...
Teva Pharmaceutical Industries Ltd.
Amsterdam (ots/PRNewswire) - Advanced MS Care Programme will offer tailored support for MS patients People living with relapsing forms of Multiple Sclerosis (MS) can now access a new Patient Support Programme (PSP) that offers tailored help based on their individual beliefs and support needs. Officially announced ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for US/UK based media Merck to Present New Data on MS Portfolio: Rebif, Mavenclad, and Evobrutinib at ECTRIMS 2017 - Important safety and immune cell analyses further characterize the selective immune reconstitution approach of Mavenclad - Continued innovation with Rebif includes analysis of NEDA and use of MAGNIMS ...
Stockholm (ots/PRNewswire) - OxThera AB, a Stockholm-based privately-held biopharmaceutical company today announced the appointment of Dr. Bastian Dehmel as their new Chief Medical Officer. OxThera is developing a novel treatment, Oxabact, for Primary Hyperoxaluria (PH), a severe and often fatal disease in children, and where there are currently no available therapies. The company is poised to initiate a pivotal Phase III ...
Waterloo, Ontario (ots/PRNewswire) - Intellijoint Surgical®, a medical technology company, is pleased to announce that it has received the approval of the CE Mark (Conformité Européenne) for its intellijoint HIP® System in Europe. A 3D Mini-Optical Navigation System, intellijoint HIP® provides surgeons with ...
Zurich, Switzerland (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of "Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis", the results of the first ...
Brussels (ots/PRNewswire) - - Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of cardiovascular disease (CVD) - Globally, CVD is the most common cause of death in people with type 2 diabetes[1] - Results from this survey will help ...
Lausanne (ots) - The 'JCA-Mauvernay Award 2017' is awarded to Doctors Yasuhiro Yamada and Hiroyoshi Nishikawa Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a Swiss-based global biopharmaceutical company, will be presenting the 'JCA-Mauvernay Award' on September 30 to Doctors Yasuhiro Yamada from the ...
Nuremberg, Germany (ots/PRNewswire) - One in three now include "take a break from technology" in their health routine. Nuremberg, September 28, 2017 - When it comes to which activities people do regularly to maintain their physical health, it is no surprise that nearly two thirds of the online population across 17 ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First-ever treatment indicated for curatively unresectable Merkel cell carcinoma (MCC) and first anti-PD-L1 to be available in Japan - Japanese Ministry of Health, Labour and Welfare (MHLW) decision based on Javelin Merkel 200 study, the largest registrational trial for an immunotherapy in MCC - First Asian approval for ...
Sunnyvale, California (ots/PRNewswire) - First Study to Evaluate the Use of Stereotactic Body Radiation Therapy in Low-Risk Prostate Cancer 10 Years Post Treatment Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent had ...
Québec City (ots/PRNewswire) - The first plant-based seasonal flu vaccine candidate reaches final clinical stage Medicago, a Canadian biopharmaceutical company and leader in the development and production of plant-based vaccines and therapeutics, is proud to announce the start of a Phase 3 efficacy study for its seasonal quadrivalent influenza vaccine (QIV) candidate. ...
Darmstadt, Germany, and New York, Usa (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK - Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland - Approval is based on ...
Reykjavik, Iceland (ots/PRNewswire) - - The generation of new mutations is a key driver of evolution but also of susceptibility to rare diseases - Fathers pass on four times as many new mutations as mothers do, but the maternal contribution is particularly strong in 10% of the genome that is prone to double-strand breaks in the helix structure of DNA - These regions have been mutational hotspots for a very long time, and ...
Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a pooled analysis of four Galderma-sponsored studies evaluating the use of topical therapies for the treatment of inflammatory papules and pustules of rosacea were presented at the 26th European Academy of Dermatology and Venereology Congress in Geneva, Switzerland. The success of rosacea treatment is ...
Lisbon, Portugal (ots/PRNewswire) - Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold higher 15 days ...
Lisbon, Portugal (ots/PRNewswire) - Oral Presentation 113 In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to basal insulin.[1] According to a new post-hoc analysis presented today at the 53rd Annual Meeting of the European ...
Lisbon, Portugal (ots/PRNewswire) - Poster # 820 A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included ...
Lisbon, Portugal (ots/PRNewswire) - Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]-[3] mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings[4]. (Logo: ...
Teva Pharmaceuticals Europe BV
Amsterdam (ots/PRNewswire) - ONLY FOR PAN-EUROPEAN/ EUROPEAN ENGLISH LANGUAGE MEDICAL TRADE MEDIA Study Highlights Improved Outcomes for Asthma Patients Including Fewer Exacerbations Following Change in Treatment to DuoResp Spiromax® Teva Pharmaceuticals Europe B.V., (NYSE and TASE: TEVA) today announced data from ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer care - Enhanced analytical capabilities to better define personalized treatment options and help predict treatment outcomes - Focused on areas of high unmet need to help enhance ...
Cambridge, England (ots/PRNewswire) - - First presentation of largest ever real-world flutiform® study at European Respiratory Society International Congress involving over 2,500 patients - Proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform pMDI New ...
Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were published in the Journal of Drugs in Dermatology. (Logo: http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg ) "This is the first ...
Cork, Ireland (ots/PRNewswire) - - Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir. The ongoing phase II ...